Humana (HUM)
(Delayed Data from NYSE)
$312.00 USD
-3.29 (-1.04%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $312.02 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
Price, Consensus and EPS Surprise
HUM 312.00 -3.29(-1.04%)
Will HUM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HUM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HUM
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
Humana (HUM), Evergreen Nephrology Partner to Improve Health Outcomes
HUM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Humana (HUM) Down 2.1% Since Last Earnings Report?
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
UnitedHealth (UNH) Rises 15% in 3 Months: Jump in or Wait out?
Other News for HUM
Texas A&M University Mays Business School and Humana Launch Annual Nationwide Healthcare Analytics Case Competition
Humana Earns 2024 Great Place To Work Certification
5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
Looking At Humana's Recent Unusual Options Activity
Humana's Falling Share Price Gives Investors An Opportunity